Fund moves
4.1%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ASBP · NASDAQ · Pharmaceutical Preparations
Aspire-Lakewood Holdings (ASBP) · oqro.io/stocks/ASBP · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$7.13−0.52 (−6.80%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Aspire-Lakewood Holdings was filed in the last 90 days. The latest on record was on Jun 10, 2025.
Since 2023, Aspire-Lakewood Holdings insiders reported 4 open-market purchases and 1 sale on Forms 4 and 5, with purchases in 1 different year, most recently 2025.
No open-market sale by an insider of Aspire-Lakewood Holdings (ASBP) was filed with the SEC in the last 90 days.
No trade in Aspire-Lakewood Holdings (ASBP) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−93.9% (−$110.11) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $117.24 on Nov 20, 2025 to $7.13 on Nov 20, 2026 (−93.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Estero, Fl.
Last 12 months
−93.9%
Market value
$10M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5,898 shares sold short (0.4% of shares outstanding), −32.2% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$6.2K
Year ended Dec 31, 2025
Net income, fiscal 2025
−$24.5M
A loss for the year
Shares outstanding
1.4M
As of Aug 7, 2026
In fiscal 2024 the company spent $13.8M buying back its own shares. Cash actually paid, from its cash-flow statement.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Traded Jun 4 – Jun 5, 2025 · largest single transaction ~$4.1K
Jun 5, 2025~$4.1K · 11K sh @ $0.39
DetailsOfficial recordJun 4, 2025~$3.7K · 9,500 sh @ $0.39
DetailsOfficial recordInsider buying
Traded Jun 5, 2025 · filed 1 day later
An Aspire-Lakewood director paid $4.1K out of pocket for Aspire-Lakewood shares. Shares held went up 111% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$63K
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $12.2M, at Jun 30, 2026
Net income, last 12 months
−$11M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Revenue and earnings history, 4 fiscal yearsRevenue breakdown: where the money goesCompared with its peers
Insiders of Aspire-Lakewood Holdings reported 4 open-market purchases and 1 sale since 2023; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $16K4×4 trades | — |
| 2023 | — | —1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Said its annual or quarterly report would be late
NT 10-Q on sec.govChanged auditor
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Deals
Things to keep in mind
Off-exchange trading: 44.9% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (8.2% on ATS, 36.7% with other brokers), close to its 23-week average of 44.8%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (21.9%), IBKR ATS (12.4%), SIGMA X2 (9.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
The three months Apr 1, 2026 to Jun 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Aug 13, 2026. Quarterly reports are not audited. Read the filing
No figure for the same quarter a year earlier
No figure for the same quarter a year earlier
No figure for the same quarter a year earlier
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 30, 2026. Read the filing
No figure for the year before
No figure for the year before
No figure for the year before
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 14,000 words.
We are an early-stage biopharmaceutical and supplements company. Aspire Biopharma Holdings, Inc. (the “Company” or “Aspire”) is a Delaware Company that was incorporated as PowerUp Acquisition Corp., a Cayman Islands exempted company, on February 9, 2021. On February 17, 2025, the Company completed the Reverse Recapitalization described below and changed its name to Aspire Biopharma Holdings, Inc. The Company engages in the business of developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Reverse Recapitalization, we were a privately held Puerto Rico corporation incorporated in September 2021.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026 and Form 10-Q filed Aug 13, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 26 more headings in the filing.
Latest annual report filed Mar 30, 2026, compared with the one filed Apr 7, 2025. Read the filing
All 35 risk factor headings match the year before, give or take wording.
There is no material litigation, arbitration or governmental proceeding currently pending against us or any members of our management team in their capacity as such.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.